

## Enhanced Genotype colorectal cancer risk test released – supports earlier disease detection and ColoSTAT® targeting

### Highlights

- ✓ Enhanced Genotype colorectal cancer (CRC) risk test now integrates genetic, clinical and lifestyle risk factors for improved risk stratification.
- ✓ New gender-specific variables deliver stronger predictive accuracy for both men and women, including younger adults.
- ✓ Peer-reviewed validation confirms improved performance versus traditional models.
- ✓ Supports identification of higher-risk individuals who may benefit from earlier screening and ColoSTAT® testing.

**Melbourne, Australia, 14th January 2026:** Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce the commercial launch of its updated geneType™ Colorectal Cancer (CRC) Risk Assessment clinical test ("geneType™ CRC"), a significant advancement in personalised cancer risk prediction. The updated test incorporates additional clinical and lifestyle risk factors alongside the established 140-SNP polygenic risk score (PRS), delivering improved predictive accuracy across both genders and a wider age range.

The enhanced test is designed to support earlier identification of individuals at elevated risk of colorectal cancer, enabling more targeted screening pathways and complementing Rhythm's ColoSTAT® blood-based CRC detection test.

Validation data for the updated model has been recently published in the peer-reviewed journal *PLOS ONE* (Dite GS, et al. 2025), demonstrating improved predictive performance compared to traditional approaches.

Evidence suggests that approximately 50% of colorectal cancer cases could be prevented through healthy lifestyle modifications. By incorporating lifestyle risk factors known to contribute to disease risk, the enhanced geneType™ CRC test aims to identify a broader cohort of at-risk individuals who may benefit from earlier intervention and monitoring.

### Key Clinical Applications

The enhanced geneType™ CRC Risk Assessment test has several important use-cases for this innovative new clinical test:

- (1) Improved risk stratification across both genders, with particular **benefits for identifying higher-risk women.**

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

[www.rhythmbio.com](http://www.rhythmbio.com)

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

T +61 3 8256 2880  
E [info@rhythmbio.com](mailto:info@rhythmbio.com)

#### Directors

Gavin Fox-Smith Non-Executive Chairman  
Sue MacLeman Non-Executive Director  
David Atkins CEO & Managing Director

(2) Identification of younger adults at risk of **early-onset colorectal cancer**, supporting earlier screening interventions.

(3) Potential to encourage greater participation in **bowel cancer screening** programs by providing personalised risk insights.

In Australia, compliance with recommended bowel cancer screening programs remains below 50%. Individuals classified as higher risk using the geneType<sup>TM</sup> CRC test may be candidates for closer clinical monitoring through colonoscopy, FIT testing, or Rhythm's blood-based CRC detection test, ColoSTAT®.

"The enhanced geneType<sup>TM</sup> CRC test strengthens our ability to identify individuals at elevated risk earlier, supporting more targeted screening and complementing ColoSTAT's® role in colorectal cancer detection." said Dr Erika Spaeth, Director of Clinical Affairs at Rhythm.

<https://coloncancerfoundation.org/dietary-mindfulness-can-reduce-the-risk-of-colorectal-cancer/>

McKinsey Health report 2024 <https://www.mckinsey.com/mhi/our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies>.

González-Flores E, *et al* Gender and sex differences in colorectal cancer screening, diagnosis and treatment. *Clin Transl Oncol.* 2025;27(7):2825-2837.

Dite GS, Wong CK, Gafni A, Spaeth E. Colorectal cancer risk prediction using a simple multivariable model. 2025;20(5):e0321641.

- ENDS -

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com).**

#### **About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

#### **About ColoSTAT®**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

#### **About geneType<sup>TM</sup>**

geneType<sup>TM</sup> is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).

For personal use only